Novo Nordisk’s $1.3 Billion Acquisition of Ocedurenone

KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP in this transaction.Novo Nordisk A/S and KBP Biosciences…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Sonia Carcano

Author: Sonia Carcano

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here